Annual report pursuant to Section 13 and 15(d)

Segments (Tables)

v3.3.1.900
Segments (Tables)
12 Months Ended
Dec. 31, 2015
Segment Reporting [Abstract]  
Operations and Assets for Operating Segments and Geographic Information
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the years ended December 31,
(In thousands)
2015
 
2014
 
2013
Revenue from services:
 
 
 
 
 
Pharmaceutical
$

 
$

 
$

Diagnostics
329,599

 
8,426

 
10,833

Corporate
140

 
240

 
825

 
$
329,739

 
$
8,666

 
$
11,658

Product revenues:
 
 
 
 
 
Pharmaceutical
$
80,146

 
$
76,983

 
$
68,161

Diagnostics

 

 

Corporate

 

 

 
$
80,146

 
$
76,983

 
$
68,161

Revenue from transfer of intellectual property:
 
 
 
 
 
Pharmaceutical
$
81,853

 
$
5,285

 
$
15,160

Diagnostics

 
191

 
1,551

Corporate

 

 

 
$
81,853

 
$
5,476

 
$
16,711

Operating (loss) income:
 
 
 
 
 
Pharmaceutical
$
(40,395
)
 
$
(94,401
)
 
$
(29,809
)
Diagnostics
(10,294
)
 
(21,647
)
 
(22,199
)
Corporate
(46,512
)
 
(27,725
)
 
(24,473
)
Less: Operating loss attributable to noncontrolling interests
(1,280
)
 
(2,042
)
 
(3,151
)
 
$
(98,481
)
 
$
(145,815
)
 
$
(79,632
)
Depreciation and amortization:
 
 
 
 
 
Pharmaceutical
$
10,245

 
$
7,936

 
$
8,234

Diagnostics
31,918

 
6,894

 
6,833

Corporate
85

 
97

 
149

 
$
42,248

 
$
14,927

 
$
15,216

Net loss from investment in investees:
 
 
 
 
 
Pharmaceutical
$
(7,105
)
 
$
(3,587
)
 
$
(11,456
)
Diagnostics

 

 

Corporate

 

 

 
$
(7,105
)
 
$
(3,587
)
 
$
(11,456
)
Revenues:
 
 
 
 
 
United States
$
344,464

 
$
14,142

 
$
28,369

Ireland
78,989

 

 

Chile
29,885

 
29,154

 
31,650

Spain
16,622

 
21,323

 
18,800

Israel
18,107

 
20,638

 
13,252

Mexico
3,671

 
5,807

 
4,459

Other


61

 

 
$
491,738

 
$
91,125

 
$
96,530


(In thousands)
December 31,
2015
 
December 31,
2014
Assets:
 
 
 
Pharmaceutical
$
1,258,011

 
$
1,064,498

Diagnostics
1,479,841

 
108,072

Corporate
61,762

 
95,094

 
$
2,799,614

 
$
1,267,664

Goodwill:
 
 
 
Pharmaceutical
$
251,225

 
$
173,327

Diagnostics
492,123

 
50,965

Corporate

 

 
$
743,348

 
$
224,292

Property, Plant and Equipment, Net by Jurisdiction
The following table reconciles our Property, plant and equipment, net between U.S. and foreign jurisdictions: 
(In thousands)
December 31, 2015
 
December 31, 2014
PP&E:
 
 
 
U.S.
$
113,307

 
$
4,286

Foreign
18,491

 
12,125

Total
$
131,798

 
$
16,411